Together these observations support that novel circadian clock-based therapeutics using Rev-erbα agonists can regulate pro-fibrotic pathways in human lung fibroblast with an implication for the treatment of pulmonary fibrosis. This evidence concerns the gene CLOCK and pulmonary fibrosis.